Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes

NCT01456130 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus

Interventions

DRUG: Alogliptin
DRUG: Rapid-acting insulin secretagogue

Sponsor

Takeda